<DOC>
	<DOCNO>NCT01103050</DOCNO>
	<brief_summary>This study determine capacity frequent dose QAV680 suppress allergic inflammation . The study investigate paradigm multiple receptor antagonism allergic disease combine QAV680 second generation H1 histamine receptor antagonist ass possible additive synergistic anti-allergic effect two compound class .</brief_summary>
	<brief_title>A Cross Over Study Compare Effect Combined Treatment With QAV680 Cetirizine</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Cetirizine</mesh_term>
	<criteria>Patients clinical history intermittent allergic rhinitis seasonal onset offset nasal allergy symptom last two ragweed allergy season positive skin prick test ragweed allergen within twelve month screen Exclusion criterion : Use medication use treat allergy ( administer via route ) , : pseudoephedrine , antihistamine , ipratropium bromide , cromoglycates , corticosteroid , immunotherapy antiinflammatory immunosuppressive agent , medication administer via nasal ocular route ) Within last three year recurrent history acute chronic bronchospastic disease include moderatesevere asthma chronic obstructive pulmonary disease Nasal condition nasal septal perforation , nasal polyp , sinus disease , chronic nasal obstruction Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Allergic inflammation</keyword>
	<keyword>Seasonal rhinitis</keyword>
</DOC>